Is CareTrust REIT (CTRE) a Solid Growth Stock? 3 Reasons to Think "Yes"

CareTrust REIT (CTRE) is identified as a strong growth stock, earning a Zacks Growth Score of B and a Zacks Rank #2. This positive outlook is supported by robust financial metrics, including a projected 21.2% EPS growth for the current year, significantly outperforming the industry average of 1%. Additionally, the company reported a year-over-year cash flow growth of 67.6% against an industry average of 2.7%, complemented by recent positive earnings estimate revisions, with the current year's Zacks Consensus Estimate increasing by 0.6% over the past month.

Analysis

CareTrust REIT (CTRE) is positioned as a strong growth candidate within the healthcare real estate sector, underpinned by exceptionally favorable forward-looking financial metrics. The company's projected EPS growth for the current year stands at 21.2%, a figure that dramatically outpaces the industry's average forecast of just 1.0%. This earnings momentum is supported by robust cash flow generation; CTRE's year-over-year cash flow has expanded by 67.6%, compared to a 2.7% average for its peers. This recent surge is contextualized by a solid historical annualized cash flow growth rate of 12.5% over the past 3-5 years, well above the 3.1% industry norm. Reinforcing this positive outlook is the recent trend in analyst sentiment, evidenced by a 0.6% upward revision in the Zacks Consensus Estimate for current-year earnings over the last month. These factors culminate in a Zacks Rank of #2 (Buy) and a Growth Score of B, suggesting a strong quantitative basis for potential market outperformance.

Key Decisions for Investors

• Given the projected 21.2% EPS growth and 67.6% year-over-year cash flow growth, investors with a focus on growth should evaluate CTRE as a potential long position, as these metrics suggest significant fundamental outperformance versus its industry.
• The recent upward revisions in consensus earnings estimates serve as a positive near-term catalyst and should be monitored as a key indicator of sustained analyst confidence.
• While forward projections are compelling, investors should consider the disparity with the company's modest historical EPS growth of 1.1% and seek to confirm the drivers behind this expected acceleration.